Colorectal carcinoma (CRC) · Regorafenib monotherapy (CORRECT-style; ReDOS escalation preferred)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`REG-REGORAFENIB`

ID	`IND-CRC-METASTATIC-3L-REGORAFENIB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ for chemo-refractory mCRC. Position vs TAS-102+bev: SUNLIGHT preferred 3L where accessible; regorafenib alternative when SUNLIGHT funding unavailable. Sequencing decision (3L → 4L) addressed in known_controversies.

Used By

Algorithms

ALGO-CRC-METASTATIC-3L - ALGO-CRC-METASTATIC-3L

Indication

IND-CRC-3L-FRUQUINTINIB - IND-CRC-3L-FRUQUINTINIB
IND-CRC-METASTATIC-3L-TAS102-BEV - IND-CRC-METASTATIC-3L-TAS102-BEV